Article
EGFR mutation testing across the osimertinib clinical program.
Lung cancer (Amsterdam, Netherlands) - 1 Jun 2025
Murat-Onana Marie Laure, Ramalingam Suresh S, Jänne Pasi A, Gray Jhanelle E, Ahn Myung-Ju, John Tom, Yatabe Yasushi, Huang Xiangning, Rukazenkov Yuri, Javey Manana, Brown Helen, Li-Sucholeiki Xiaocheng
Abstract excerpt
OBJECTIVES: EGFR-tyrosine kinase inhibitors, including osimertinib, have revolutionized EGFR-mutated non-small cell lung cancer (NSCLC) treatment; therefore, early identification of EGFR mutations is essential. We report post-hoc analyses of pooled EGFR mutation tissue testing across osimertinib clinical trials, highlighting testing challenges and supporting best practice. MATERIALS AND METHODS: Pooled central...
Read the complete abstract on PubMedTopics
- Humans
- ErbB Receptors
- Acrylamides
- Aniline Compounds
- Lung Neoplasms
- Mutation